Cost-effectiveness of carfilzomib (Kyprolis) (in combination with lenalidomide and dexamethasone) for the treatment of adult patients with multiple myeloma who have received at least one prior therapy
ثبت نشده
چکیده
lenalidomide and dexamethasone) for the treatment of adult patients with multiple myeloma who have received at least one prior therapy The NCPE has issued a recommendation regarding the cost-effectiveness of carfilzomib (Kyprolis®). Following NCPE assessment of the applicant’s submission, carfilzomib (Kyprolis®) (in combination with lenalidomide and dexamethasone) is not considered cost-effective for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.
منابع مشابه
The European Medicines Agency Review of Carfilzomib for the Treatment of Adult Patients with Multiple Myeloma Who Have Received at Least One Prior Therapy
On November 19, 2015, a marketing authorization valid through the European Union was issued for carfilzomib in combination with lenalidomide and dexamethasone for the treatment of adult patients with multiple myeloma (MM) who have received at least one prior therapy.In a phase III trial in patients with relapsed MM, median progression-free survival (PFS) for patients treated with carfilzomib in...
متن کاملCost-Effectiveness of Lenalidomide-Plus-Dexamethasone in Multiple Myeloma Patients Who Have Received at Least One Prior Therapy: A South Korean Perspective.
treatments with respect to PFS were estimated through a survival analysis of patient-level data (Celgene data on file). Due to the potential of crossover/subsequent treatment options induced bias, OS was estimated using a quantitative relationship between PFS and OS from a censored normal weighted Tobit regression model, based on 153 MM studies containing 230 treatment arms7. In this study, Fél...
متن کاملDaratumumab monotherapy compared with historical control data in heavily pretreated and highly refractory patients with multiple myeloma: An adjusted treatment comparison
Daratumumab is a human CD38-directed monoclonal antibody approved in the United States as monotherapy for patients with multiple myeloma (MM) who have received ≥3 prior lines of therapy (LOTs), including a proteasome inhibitor (PI) and an immunomodulatory agent (IMiD) or who are double refractory to a PI and an IMiD, and in combination with lenalidomide/dexamethasone or bortezomib/dexamethasone...
متن کاملNew drugs in multiple myeloma – role of carfilzomib and pomalidomide
Carfilzomib (CFZ), an epoxyketone with specific chymotrypsin-like activity, is a second-generation proteasome inhibitor with significant activity in patients with relapsed and refractory multiple myeloma. On July 20, 2012, the US Food and Drug Administration approved CFZ to treat patients with multiple myeloma who have received at least two prior therapies including bortezomib (BORT) and an imm...
متن کاملNew developments in the management of relapsed/refractory multiple myeloma – the role of ixazomib
Ixazomib is the first oral proteasome inhibitor to be approved, in combination with lenalidomide and dexamethasone, for the treatment of patients with multiple myeloma who have received at least one prior therapy. Approval was on the basis of results from the phase 3, double-blind, placebo-controlled TOURMALINE-MM1 study, which demonstrated a 35% improvement in progression-free survival with th...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
دوره شماره
صفحات -
تاریخ انتشار 2016